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beta-1b (interferons) and natalizumab and the reactions suspected of being asso-
ciated with them were identified. Disproportionality analyses used the Multi-item
Poisson Gamma Shrinker method with WHO-ART diagnosis at the preferred term
level for all AEs and for the standard combination of all WHO =critical terms=.
Statistical significance for disproportionality was defined as an Empirical Bayesian
Geometric Mean lower fifth percentile (EBGM05) 2.0. Comparisons were made
between GA versus all other drugs and GA versus interferons and natalizumab.
Sales data for GA were available to calculate reporting rates. RESULTS: A total of
2,320 cases with 6,680 AEs with a suspected relationship with GA and 20,155 cases
with 72,326 AEs for interferons and natalizumab were identified. Compared with all
other drugs in Vigibase and with interferons and natalizumab, GA was associated
with several statistically significant observations of disproportionate reporting.
WHO =critical terms= combined were not higher for GA versus interferons and
natalizumab (EBGM of 0.84 (90% credibility interval 0.79-0.90). The reporting rate of
WHO =critical terms= for GA was 69 events/100,000 person-year. CONCLUSIONS: In
a risk-benefit analysis of GA based on traditional meta-analysis, the number of AEs
in eligible controlled placebo/untreated and head-to-head studies were limited. In
such a situation analysis of a global large spontaneous AEs database permitted the
assessment of non-common and important risks. However, the biases inherent in
these databases need to be addressed.
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OBJECTIVES:Ambulation is the most highly valued bodily function for MS patients
(Heesen et al.), with ambulation problems recorded in up to 75% of patients (Hobart
et al.). Fampridine is a first-in-class treatment for ambulation. It improves the
conductivity of the nerves where demyelination has occurred. A preliminary bud-
get impact model (BIM) has been created to analyse the impact of introducing
fampridine to treat MS patients with walking impairment in the UK market.
METHODS: The BIM calculates the budget impact from a UK payer perspective of
introducing fampridine in addition to usual care to an eligible MS patient popula-
tion suffering from ambulation problems with an Expended Disability Severity
Scale (EDSS) between 4 and 7.5, using a 3 year time horizon and a market forecast.
The model conservatively assumes that all patients respond to treatment and
there is no effect of fampridine on usual care resource use. A monthly withdrawal
rate is also applied. RESULTS: The acquisition cost of fampridine is estimated at
£3800 per patient per year. An approximate eligible population of 35,000 MS pa-
tients is estimated from literature. The market forecast estimates an uptake of 3%,
10% and 16% of the eligible population in the first three years respectively, and the
estimated withdrawal rate is 2.2%. Compared to usual care alone, the annual re-
sults for the first three years show an additional budget of £3.4million, £10.9million
and £18.2million respectively. CONCLUSIONS: The model presents conservative
estimates whilst still showing a relatively low impact on the payer’s budget, dem-
onstrating that a major unmet need of MS patients can be met without a large
increase in budget. Further research is required into response rates, effect of fam-
pridine on usual care treatment costs to get a more accurate estimate of the impact
fampridine.
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OBJECTIVES: To assess the budget impact of the treatment for Relapsing Remitting
Multiple Sclerosis (RRMS), interferons, and glatiramer acetate, from the National
Health System (NHS) perspective.METHODS:A budget impact model was designed
to compare the cost of RRMS treatment in different settings, using a 5 year time-
horizon, considering different percentages of administration of each medication. A
reference setting o base case using all the available first line treatments (interfer-
ons and glatiramer acetate) was compared with 5 alternatives scenarios excluding
each one of these treatments. The cost analysis (2010 euros) includes direct med-
ical resources (drugs, administration, visits, disease management, diagnostic
tests). Unitary cost data was obtained from the health costs database e-Salud and
drugs Catalogue. RESULTS: Considering a cohort of 22,255 patients with RRMS, the
mean global budget impact per year would be € 260.775.470 in the base case. The
setting that excluded glatiramer acetate increases the budget impact in a 3.23% (€
372 per patient per year). Pharmacological costs were the key drivers of total cost
(90%). CONCLUSIONS: The use of glatiramer acetate in the first-line-treatment of
RRMS patients is a cost-saving strategy, which may decrease the budget impact
from the NHS perspective in Spain.
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OBJECTIVES: To estimate costs of managing corticosteroid (CS)-related adverse
events (AEs) within a systemic lupus erythematosus (SLE) population.METHODS:A
retrospective claims analysis (January 1, 2000–June 30, 2010) was conducted within
an SLE population to evaluate the risk of known CS-related chronic and acute AEs
among CS users and non-users by utilizing Cox proportional hazards models ad-
justing for patient characteristics, SLE severity, other SLE treatments, and AE-re-
lated risk factors. Associated costs were computed for AEs where the risk was
significantly different among CS users compared to non-users. CS users having a
chronic AE were followed for 12 months post-AE date to capture total costs, which
were compared to total costs of CS users who did not have a chronic AE during the
same time period. Predicted annual costs were generated using generalized linear
models controlling for baseline characteristics. The incremental difference in an-
nual costs among the two groups was considered attributable to the AE. For pa-
tients having an acute AE, disease-specific costs were calculated over a 12-month
timeframe post-AE date. RESULTS: SLE patients receiving CS were more likely to
develop chronic AEs (ie, cataracts, sleep disturbances, hypertension, type II diabe-
tes, migraine) and acute AEs (ie, pneumonia, herpes zoster, fungal infections, nau-
sea/vomiting). The average annual cost for managing AEs was highest for type II
diabetes ($9763), followed by hypertension ($8774), sleep disturbances ($5599), mi-
graine ($3591), cataracts ($2407), herpes zoster ($2079), pneumonia ($1726), nausea/
vomiting ($1357), and fungal infections ($857). When applying base rates and in-
creased risk estimates of each AE to the cost estimates, it costs an additional
$784/year per CS user to manage known CS-related AEs compared to CS non-users.
CONCLUSIONS: Within an SLE population, CS treatment is associated with addi-
tional costs of $784/year due to management of CS-related AEs. Providers and
payers should consider these potential costs of CS when making treatment deci-
sions.
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OBJECTIVES: Approximately 50% of patients do not achieve seizure control with a
single antiepileptic drug (AED). With the advent of multiple AEDs in the past 15
years, the choice of optimal polytherapy remains difficult in absence of clinical
studies about the effectiveness of various combination therapies. This study aimed
at describing the current management of focal epilepsy treated by polytherapy in
France and at estimating the extra-costs of pharmacoresistance (PR) as redefined in
2009 by the International League Against Epilepsy (ILAE). METHODS: ESPERA is a
European multicenter, observational, cross-sectional study conducted in France
and Spain in 2010. A random sample of neurologists enrolled prospectively a sam-
ple of adult patients treated with at least two antiepileptic drugs (AEDs) in combi-
nation for focal epilepsy. The investigators classified their patients according to the
new ILAE criteria and this classification was then reviewed by two independent
experts. All items of medical resources use associated with epilepsy were collected
retrospectively over the last year and valued according to a societal perspective.
RESULTS: Seventy-one French neurologists collected analysable data on 405 pa-
tients. After review by experts, patients were finally classified as PR in 286 (70.6%) of
them, in 91 (22.4%) as responsive and in 28 (7%) as undefined. The mean annual
epilepsy related direct costs par patient were 4238 € (SD: 3772) in PR patients as
compared with 1907€ (SD: 1,739) in responsive patients. AEDs costs were estimated
2602€ and 1544€ respectively and PR patients were significantly more often hospi-
talized (mean annual cost: 1023€ versus 78€) and had more procedures (mean an-
nual cost: 194€ versus 53€). CONCLUSIONS: Despite the number of therapeutic
alternatives available in epileptic patients, a large proportion of them remain with
uncontrolled seizures yielding to significant extra costs.
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OBJECTIVES: To compare the expected costs (EC) of three different screening strat-
egies for cystic fibrosis implemented in Spain: TIR/DNA/DGGE, TIR/TIR/DNA, and
TIR/DNA. These strategies correspond to screening programs in Basque Country,
Castilla León and Canary Islands. METHODS: For each strategy, EC per child
screened, also EC per infant with CF and EC disaggregated by type of test was
estimated. In addition, sensitivity of each strategy was calculated. Unless there are
differences between unit cost along communities, the same unit cost source for all
programs was used, in order to allow comparisons. RESULTS: The estimated EC per
screened neonate were € 3.67, € 4.07, € 4.11 for TIR/ADN, TIR/ADN/DGGE, and TIR/
TIR/ADN respectively, showing that TIR/ADN/DGGE is the strategy with lowest EC
for its population. Regarding the sensitivity of the three strategies, the results
showed similar and high values for all of them, being the strategy of Basque Coun-
try which had highest value (99.37%). The ECs per neonate suffering CF were
82.703,48 €, 18.726,29 €, 16.604,10 € for TIR/ADN, TIR/ADN/DGGE, and TIR/TIR/ADN
respectively, showing highest cost per neonate with the disease, however the
power of this results is still low, and there are differences between incidences along
strategies. CONCLUSIONS: In this cost comparative study it was obtained that the
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